Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2015; 21(46): 13087-13094
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087
Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study
Ming-Hua Su, Ai-Lian Lu, Shi-Hua Li, Shao-Hua Zhong, Bao-Jian Wang, Xiao-Li Wu, Yan-Yan Mo, Peng Liang, Zhi-Hong Liu, Rong Xie, Li-Xia He, Wu-Dao Fu, Jian-Ning Jiang, Department of Infectious Disease, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Author contributions: Jiang JN designed the research; Su MH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P and Liu ZH performed the research; Li SH, Lu AL and Su MH analyzed data; Xie R, He LX and Fu WD contributed new reagents or analytic tools; Su MH and Lu AL wrote the paper.
Supported by the Natural Science Foundation of Guangxi, No. 2014GXNSFDA118023.
Institutional review board statement: The study was approved by the Human Ethics Committee of the First Affiliated Hospital of Guangxi Medical University.
Informed consent statement: All study participants or their legal guardian provided informed written consent regarding personal and medical data collection prior to study enrollment.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest related to the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jian-Ning Jiang, Professor, Department of Infectious Disease, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Qingxiu District, Nanning 530021, Guangxi Zhuang Autonomous Region, China. jjianning@163.com
Telephone: +86-771-5301670
Received: May 24, 2015
Peer-review started: May 25, 2015
First decision: June 25, 2015
Revised: August 11, 2015
Accepted: September 30, 2015
Article in press: October 8, 2015
Published online: December 14, 2015
Processing time: 198 Days and 20.2 Hours
Peer-review started: May 25, 2015
First decision: June 25, 2015
Revised: August 11, 2015
Accepted: September 30, 2015
Article in press: October 8, 2015
Published online: December 14, 2015
Processing time: 198 Days and 20.2 Hours
Core Tip
Core tip: Drug resistance and disease relapse are inevitable during long-term lamivudine treatment in some patients. However, as long as standardized procedures in combination with comprehensive management are used, viral replication can be inhibited to a large extent. Thus, liver function in patients can be maintained at a stable status for a long time, and the incidence rates of liver cirrhosis and hepatocellular carcinoma, as well as hepatitis B virus-related deaths, may be reduced.